Before you sell to, join or invest in Sequence Bio
MentionFox check on Sequence Bio: only 1 source on file so far (checked 5 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/yc-sequence-bio
Check Sequence Bio before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Sequence Bio?
Based on the record MentionFox holds for this company. No flag is not a clearance.
90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that.
Sequence Bio is a Y Combinator company in the Summer 2019 batch. Its directory entry describes it as: Discovering the true signals of disease to power life-changing drugs. The founders listed are Jeremy Grushcow (Founder), Chris Gardner (Founder) (Y Combinator directory entry, June 19, 2019).
Sell to companies like Sequence Bio? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2019-06-19 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Sequence Bio.
Free to see. No signup.
More on Sequence Bio and the records around it.
Same batch, Healthcare first.
Get an email when Sequence Bio changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Sequence Bio raises, hires or launches. No email unless you switch it on.
Watch Sequence Bio →Get the full cited report on Sequence Bio
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Sequence Bio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Sequence Bio: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sequence Bio covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Sequence BioYou get an alert in MentionFox the next time this company shows up.
If you're behind Sequence Bio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Sequence Bio. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.
https://mentionfox.com/funding/yc-sequence-bio